Opendata, web and dolomites

TCRabX SIGNED

Structural basis for the therapeutic efficiency of optimal-affinity T cell receptors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TCRabX project word cloud

Explore the words cloud of the TCRabX project. It provides you a very rough idea of what is the project "TCRabX" about.

form    alternative    diverse    population    recognizing    treatment    germany    middle    mice    mediated    analysed    cancer    benefit    made    13    patient    lymphocytes    health    structural    dimensional    uncovered    biology    ageing    self    cell    efficient    regression    optimal    genes    types    surgery    human    macromolecules    world    humanized    elderly    berlin    mhc    beta    affinity    complementarity    ray    cognate    regions    transfer    newly    rates    class    cdrs    immunology    naturally    aged    contact    crystallography    pmhc    alpha    citizens    cells    helps    delay    demographic    radiation    gene    negative    supporting    incidence    structures    melbourne    therapeutic    chemotherapy    receptor    points    determined    antigens    loaded    complexed    topologies    repertoire    innovative    people    respectively    hugely    biological    tcrabx    trials    tcr    exceptional    immunotherapy    3d    tumour    interdisciplinary    blood    date    peptide    cdr    australia    powerful    molecules    tcrs    isolated    therapy    begin    therapeutically    docking    peripheral    identification    connects    specificity    clinical    antigen    chains    biomedical    worldwide    tool    histocompatibility   

Project "TCRabX" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 264˙110 €
 EC max contribution 264˙110 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2022-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 264˙110.00
2    MONASH UNIVERSITY AU (VICTORIA) partner 0.00

Map

 Project objective

Demographic change includes population ageing, and incidence rates begin to increase for many types of cancer in middle-aged and elderly people. Traditional cancer treatment includes surgery, chemotherapy, and radiation therapy, while tumour immunotherapy by T cell receptor (TCR) gene transfer represents an alternative form of treatment. The transfer of tumour-specific TCR genes into patient’s peripheral blood lymphocytes targets cancer specifically and effectively. But while patient-derived low-affinity TCRs do not show therapeutic activity, optimal-affinity TCRs, as isolated from newly-generated antigen-negative humanized mice with a diverse human TCR repertoire, can effectively delay tumour regression. X-ray crystallography is a powerful tool of structural biology, which helps researchers to identify the three-dimensional (3D) structures of biological macromolecules such as TCRs complexed to their cognate peptide-loaded major histocompatibility complex (pMHC) molecules. Recent research uncovered the docking topologies of naturally selected TCRs, but therapeutically efficient optimal-affinity TCRs recognizing tumour-associated self-antigens, have not been analysed to date. The exceptional specificity of TCRs is determined by three complementarity-determining regions (CDRs) of the TCR alpha- and beta-chains. Biomedical research on TCR gene therapy and design of future clinical trials will hugely benefit from the identification of CDR-mediated contact points made between therapeutic TCRs and the pMHC on their target cells. TCRabX is an interdisciplinary research project investigating the 3D structures of 13 TCRs complexed to MHC-I or MHC-II, respectively. It connects innovative clinical immunology research in Berlin/Germany and world-class structural biology research in Melbourne/Australia. The proposed research will enhance the health and well-being of citizens in Europe and worldwide by supporting the advancement of cancer immunotherapy approaches.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TCRABX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TCRABX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More